Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Medicenna Therapeutics Corp. has unveiled promising preclinical data showcasing the potential of their novel therapies, MDNA11 and Bizaxofusp, in treating aggressive cancers like glioblastoma. These therapies work together to boost immune response and weaken the tumor microenvironment, offering hope for cancers resistant to current treatments. The combination of MDNA11 and Bizaxofusp could revolutionize cancer treatment strategies, particularly for tumors known as ‘cold tumors.’
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Shareholder Alert for Chipotle Mexican Grill, Inc. (NYSE:CMG)
- 3 Penny Stocks to Watch Now, 11/26/24
- Rivian Gets Conditional DOE Loan of $6.6B for Georgia Plant
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
